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“HE WAS LIKE A ZOMBIE”: OFF-LABEL PRESCRIPTION OF 
ANTIPSYCHOTIC DRUGS IN DEMENTIA 
 
Rosie Harding, University of Birmingham, UK & Elizabeth Peel, Aston University, UK.* 
Abstract: This paper explores the legal position of the off-label prescription of antipsychotic 
medications to people with dementia who experience behavioural and psychological symptoms of 
dementia (BPSD). Dementia is a challenging illness, and BPSD can be very difficult for carers to 
manage, with evidence that this contributes to carer strain and can result in the early 
institutionalisation of people with dementia. As a result, the prescription of antipsychotic and other 
neuroleptic medications to treat BPSD has become commonplace, in spite of these drugs being 
untested and unlicensed for use to treat older people with dementia. In recent years, it has become 
apparent through clinical trials that antipsychotic drugs increase the risk of cerebrovascular accident 
(stroke) and death in people with dementia. In addition, these types of medication also have other 
risk factors for people with dementia, including over-sedation and worsening of cognitive function. 
Drawing on recent questionnaire (n=185), focus group (n=15) and interview (n=11) data with carers 
of people with dementia, this paper explores the law relating to off-label prescription, and the 
applicability of medical negligence law to cases where adverse events follow the use of antipsychotic 
medication. It is argued that the practice of off-label prescribing requires regulatory intervention in 
order to protect vulnerable patients. 
Keywords: Off-label; antipsychotics; dementia; Alzheimer’s disease; medical negligence; tort 
*** 
Dementia is an extremely common disease, which predominantly affects older people. There are an 
estimated number of 25 million people with dementia worldwide.1 Research commissioned by the 
Alzheimer’s Society,2 which has been accepted by the National Audit Office (NAO) as providing the 
most accurate figures available,3 estimates that there were 683,597 people living with dementia in 
the UK in 2007. This figure includes at least 15,034 people with younger onset dementia (dementia 
diagnosed before the age of 65), and total numbers are estimated to increase to over 1 million by 
                                                          
* The authors would like to thank Susan Westwood and Bradley Crook for their excellent research assistance 
and Tsachi Keren-Paz, Michael Thomson and the anonymous reviewers for their helpful comments on an 
earlier version of this article. 
1
 CP Ferri, M Prince, C Brayne et al. Alzheimer’s Disease International ‘Global prevalence of dementia: a Delphi 
consensus study’ (2005) 366 Lancet 2112-2117. 
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 M Knapp, M Prince, E Albanese, S Banerjee, S Dhanasiri, JL Fernandez, C Ferri , P McCrone, T Snell, R Stewart 
Dementia UK: A Report to the Alzheimer’s Society on the prevalence and economic cost of dementia in the UK 
(Alzheimer’s Society, London, 2007). 
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 National Audit Office Improving services and support for people with dementia: Report by the comptroller and 
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2025, given trends towards an ageing population.4 Many people with dementia experience one or 
more of the behavioural and psychological symptoms of dementia (BPSD) which can include a 
variety of problems including delusions, hallucinations, depression, anxiety, sleeplessness, 
wandering, agitation and physical aggression.5 It has been suggested that BPSD can occur in up to 
90% of people with Alzheimer’s disease, which is the most common variant of dementia.6 BPSD 
contribute significantly to carer strain,7 and can result in the hospitalisation and/or early 
institutionalisation of people with dementia.8 Historically, these symptoms of dementia were most 
commonly treated with antipsychotic medications.9 
In a recent report for the British Government investigating the use of antipsychotic medication for 
people with dementia in the NHS in England, Professor Sube Banerjee reported that antipsychotics 
were over-prescribed in dementia, and that there were significant risks of harm to people with 
dementia from the prescription of these medications.10 It is estimated that up to 180,000 people 
with dementia are treated with antipsychotic medication in England each year, at a cost of £90 
million.11 As such, the prescription of antipsychotic medication forms part of the treatment of a 
significant proportion (up to 25%) of people with dementia each year, at significant cost to the NHS. 
Only one atypical antipsychotic medication, Risperidone, is currently licensed for use in people with 
dementia for treating persistent aggression in “patients with moderate to severe Alzheimer’s 
dementia unresponsive to non-pharmacological approaches and where there is a risk of harm to self 
or others”.12 It is only licensed for use for short periods (up to 6 weeks). In contrast to this licensed 
use, a wide variety of antipsychotic medications are prescribed ‘off-label’. Off-label prescribing is the 
term given to the act of prescribing a medication for the treatment of either a medical condition or 
patient group that is not included on the marketing authorisation from the Medical and Healthcare 
products Regulatory Agency (MHRA).13 Off-label prescribing is both legal and commonplace, falling 
as it does within the professional judgment of the prescribing medical professional. Off-label 
prescribing must be contrasted with 'unlicensed' drug use, which has been defined as "all uses of a 
                                                          
4
 Knapp et al (n 2). Prevalence rates for dementia increase with age: 40-64 years: 1 in 1400, 65-69 years: 1 in 
100, 70 – 79 years, 1 in 25, 80+ years 1 in 6. (Alzheimer’s Society website: 
http://www.alzheimers.org.uk/site/scripts/documents_info.php?categoryID=200167&documentID=412, 
accessed August 2010) 
5
 National Collaborating Centre for Mental Health Dementia: a NICE-SCIE Guideline on supporting people with 
dementia and their carers in health and social care. National Clinical Practice Guideline no. 42. (Leicester: 
British Psychological Society 2011). (NICE Dementia). 
6
 P.H. Robert et al. ‘Grouping for behavioral and psychological symptoms in dementia: clinical and biological 
aspects’ Consensus paper of the European Alzheimer disease consortium. (2005) 20 European Psychiatry 490–
496. 
7
 C Donaldson, N Tarrier and A Burns ‘The impact of the symptoms of dementia on caregivers’ (1997) 170 The 
British Journal of Psychiatry 62–68. 
8
 S Banerjee, J Murray, B Foley, L Atkins, J Schneider, A Mann ‘Predictors of institutionalisation in people with 
dementia’ (2003) 74 Journal of Neurology, Neurosurgery & Psychiatry 1315-1316. 
9
 S Banerjee The use of antipsychotic medication for people with dementia: Time for action (London, 
Department of Health 2009). 
10
 Banerjee, (n 9). 
11
 Alzheimer’s Society website ‘Facts on Antipsychotic Drugs’ available at 
http://alzheimers.org.uk/site/scripts/documents_info.php?documentID=535&pageNumber=3, accessed on 01 
March 2012;  Banerjee, (n 9) 51. 
12
 NICE Dementia (n 5). 
13
 A Neubert, M Felisi, A Bonifazi, C Manfredi, ICK Wong and A Ceci ‘Off-label and unlicensed use of medicines 
for children’(2009) 11 Pharmaceuticals Policy and Law 41–49. 
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drug which has never received a European Marketing Authorisation as medicinal for human use in 
either adults or children."14  
There are a number of specific risks of harm associated with the use of antipsychotic medications to 
treat people with dementia. These include an increased risk of cerebrovascular accident (stroke), 
and an increased risk of death.15 These risks were quantified in Banerjee’s report as equating to 
1,620 additional cerebrovascular accidents per annum in people with dementia, and 1,800 deaths, 
based on an estimate of 180,000 people per annum being treated with antipsychotics.16 Of most 
concern is the increased mortality risk, which Banerjee estimates based on short term (6-12 week) 
prescription. Where longer term treatment is used, the mortality risk is even higher: "longer-term 
treatment may result in up to 167 additional deaths among 1,000 people with dementia treated with 
antipsychotics over a two-year period".17 This amounts to a 16.7% mortality rate for long-term 
prescription of antipsychotic medications to people with dementia; an extraordinarily high incidence 
of such a severe adverse effect of medication.  
Such a high manifestation of adverse effects of medical practice raises important legal questions that 
must be addressed, and are the focus of this paper. The first question that arises is how it is possible 
for medications that have such high risks attached to them to be prescribed ‘off-label’ to a 
vulnerable population such as people with dementia. Part 1 provides an overview of the operation 
of the regulatory framework surrounding prescription medication, including statutory regulation and 
the ‘soft law’ approaches that supplement it. We interrogate the legality of off-label prescription of 
medications, highlighting key flaws in the regulation of this aspect of medical practice. In Part 2, we 
turn to some of the empirical findings from the Duties to Care18 dementia project and the Dementia 
Talking project.19 Drawing on carers responses to a questionnaire (n=185), and qualitative comments 
from participants in focus groups (n=15) and interviews (n=11), we demonstrate the ways that the 
potential harm caused by the off-label prescription of antipsychotic medication are experienced by 
carers of people with dementia, highlighting the limitations of the current law in this area. In Part 3 
we build on this analysis to emphasise the limitations of the current regulatory regimes of medicines 
regulation and medical negligence in respect of off-label prescribing. We explore whether there are 
currently appropriate legal remedies available to people with dementia who suffer harm through the 
use of off-label prescriptions of antipsychotic medication. Finally in Part 4, we present an argument 
for reform of the legal frameworks surrounding off-label prescribing of antipsychotic medication to 
control the non-cognitive symptoms of dementia. 
I: OFF-LABEL PRESCRIBING 
                                                          
14
 ibid, 47. 
15
 LS Schneider, KS Dagerman and P Insel ‘Risk of death with atypical antipsychotic drug treatment for 
dementia: meta-analysis of randomized placebo-controlled trials’ (2005) 294 Journal of the American Medical 
Association 1934-1943. 
16
 Banerjee, (n 9) 28. 
17
 ibid, 27. 
18
 R Harding and E Peel, ‘Duties to Care: A socio-legal study of caring for people with dementia’, funded by the 
British Academy Small Grant SG1000017 (2010-2012). 
19
 E Peel, ‘Dementia Talking: Care, conversation and communication’, funded by the British Academy Mid-
Career Fellowship (2011-2012). 
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A: Licensing of Medicines 
In the UK, prior to being made available for public use, all medicinal products must have a marketing 
authorisation from the MHRA.20 In order to grant a licence for a medication, the MHRA must satisfy 
itself that the medication is relatively safe, effective and of consistent quality.21  The aim of having a 
licensing system for medications is to protect public health by ensuring that prior to being made 
available to patients, all medications must be tested through clinical trials to ensure that they are 
effective, and that the risk profile of side effects is not so great as to outweigh any benefit from 
them.22 Marketing authorisations are time-limited, and manufacturers must apply for a renewal of 
the product license at least every five years, thus giving an opportunity to present data from 
additional trials, and perhaps to extend the licensed use of particular medications.23 As part of the 
licensing process, manufacturers must submit full information about research that has taken place 
into the medication, the results of trials and any adverse reactions. They must also provide 
information about how the medication is made, the quality control processes the manufacturer 
uses, and information about how the medication will be marketed including any patient information 
leaflets that will be supplied with the product.24 
The legislative framework for medication classifies medicines into three categories: 1) prescription 
only medications;25 2) medications that can be supplied by a pharmacist26 without prescription; and 
3) general sale list27 medicines that do not need to be sold by a pharmacist. Medications that are 
likely to present a direct or indirect danger to human health; are frequently or widely used 
incorrectly; contain substances which require further investigation; or are normally prescribed 
intravenously are usually prescription only.28 Additionally, where a medicine is likely to present a 
substantial risk of addiction, or is likely to be abused, it will be a prescription only medication.29 
Where a medicine is prescription-only, it can only be supplied following prescription by an 
                                                          
20
 Medicines Act 1968, s. 7. Where the medication is for the treatment of HIV/AIDS, cancer, diabetes, 
neurodegenerative diseases, auto-immune and other immune dysfunctions, and viral diseases, the marketing 
authorisation will be granted by the European Medicines Agency (EMEA) which was established by Regulation 
(EC) No. 726/2004 OJ L 136, 30.4.2004, and is governed by Council Directive 2001/83/EEC on the Community 
Code Relating to Medicinal Products for Human Use OJ – 311, 28.11.2004 (as amended). The MHRA is a 
national competent body under the EMEA,  
21
 Medicines Act 1968, s. 19. 
22
 Medicines and Healthcare products Regulatory Agency website, available at: 
http://www.mhra.gov.uk/Aboutus/Whoweare/index.htm accessed on 16 March 2012. 
23
 ibid, at 
http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Marketingauthorisations/index.ht
m#11 accessed on 16 March 2012. 
24
 MHRA Medicines and Medical Devices Regulation: What you need to know (2008) available at 
http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con2031677.pdf, accessed 
on 16 March 2012. 
25
 Medicines Act 1968, s. 58. 
26
 Medicines Act 1968, s. 52. 
27
 Medicines Act 1968, s. 51. 
28
 Medicines Act 1968, s. 58A(2). 
29
 Medicines Act 1968, s. 58A(3). 
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appropriate practitioner.30 Once a medicine has a marketing authorisation, it can be freely 
prescribed by an appropriate practitioner31 and subsequently supplied by a pharmacist.  
There is also a complex array of post-license regulation: manufacturers must provide specific 
information on the labelling and in the patient information leaflet supplied with medicines.32 There 
are restrictions concerning the marketing of products, and in the UK prescription-only medications 
cannot be directly marketed to the general public.33 Marketing medications to healthcare providers 
is authorised, and pharmaceutical companies go to great lengths to sell their products to healthcare 
professionals, including funding continuing professional development for medical professionals.34 
There are also post-marketing processes for the identification of adverse drug reactions, and the 
reporting of these to the MHRA. In particular, there is a ‘Black Triangle’ scheme for new drugs, which 
are monitored closely for the first two years of their license, during which time there is a 
requirement to notify all adverse reactions. For other drugs, only serious suspected reactions must 
be notified, though all reactions can be notified either by health professionals or members of the 
public through the ‘Yellow Card Scheme’.35 There is, however, no restriction placed on the uses of 
medicines which have a marketing authorisation through the current regulatory framework. 
Prescription only medications can therefore be prescribed for conditions or patient groups other 
than those for which they were designed, tested and licensed. Uses of medicines other than those 
on the marketing authorisation are often referred to as ‘off-label’ prescription. 
The practice of off-label prescription is commonplace, and is an important tool for medical 
professionals. This is particularly true in paediatric practice, where only very few medicines have 
specific licenses for use with children, in part due to the legal and ethical difficulties associated with 
testing drugs on minors. As such, off-label (and unlicensed) medications are regularly prescribed to 
children in hospital settings. For example, research has suggested that off-label prescription 
accounts for over 70% of medication used to treat children in an intensive care unit,36 and over a 
third of prescribing on in-patient children’s wards in Europe.37 Similarly, most medications are tested 
on, and therefore licensed for use, in adult populations under the age of 70. Despite the 
commonplace nature of off-label prescription, however, the regulation of this practice is felt to be 
unsatisfactory both for patients and doctors.38 A key reason why the current framework is felt to be 
unsatisfactory is that in the absence of specific regulation relating to off-label uses, responsibility for 
harm ultimately lies with the individual prescriber, subject to the common law rules of medical 
                                                          
30
 Medicines Act 1968, s. 58. 
31
 ibid, s. 58. 
32
 Medicines (Labelling) Regulations 1976 SI 1976/1726, as amended; Medicines (Leaflets) Regulations 1977 SI 
1977/1055, as amended. 
33
 Medicines (Advertising) Regulations 1994 SI 1994/1932, as amended. 
34
 Royal College of Physicians Innovating for Health: Patients, the Pharmaceutical Industry and the NHS (RCP, 
London 2009). 
35
 MHRA Yellow Card Scheme available at: http://yellowcard.mhra.gov.uk/ accessed on 16 March 2012. 
36
 GW ‘t Jong, AG Vulto, M de Hoog, et al. 'Survey of the use of off-label and unlicensed drugs in a Dutch 
children’s hospital' (2001) 108 Pediatrics 1089–1093. 
37
 S Conroy, et al. 'Survey of unlicensed and off label drug use in paediatric wards in European countries' (2000) 
320 BMJ 79–82. 
38
 P Hill, ‘Off licence and off label prescribing in children: litigation fears for physicians’ (2005) 90 (Suppl I) 
Archives of Disease in Childhood i17-i18. 
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negligence.39 The regulation of off-label prescription of medicines therefore falls at the intersection 
of two legal regimes. The first is a complex statutory regime, concerned with determining the safety 
of drugs prior to their use in practice; the second is the common law regime governing the tort of 
negligence. We now turn to explore how the prescription of antipsychotic medication for treating 
the behavioural and psychological symptoms of dementia fits within this dual regime. 
B: Antipsychotics and Dementia 
Antipsychotic medications have been used for decades to sedate, calm and control people with 
dementia.40 These drugs are used to treat BPSD, sometimes also referred to as 'non-cognitive' 
symptoms. Antipsychotics do not slow the progression of the disease, nor remove the cause of, or 
trigger for BPSD. Often (but by no means always), BPSD are as a result of difficulties in 
communication and can be the result of a complex array of factors associated with both the 
progression of dementia, and a range of other "psychosocial factors, which interact with biological 
factors and influence greatly the presenting picture."41  
As we mentioned earlier, at present only one antipsychotic medication (Risperidone) has a 
marketing authorisation from the MHRA that includes the treatment of BPSD. This licence followed a 
period of over six years when Risperidone (along with another atypical antipsychotic, Olanzapine) 
was explicitly contra-indicated for people with dementia, following guidance issued by the 
Committee on the Safety of Medicines (CSM) that the risk of stroke outweighed any modest benefits 
associated with the use of these drugs in controlling BPSD.42  The limitations on the prescribing 
period are particularly important, as this seems to be out of line with current practices in relation to 
the prescription of antipsychotic medication to people with dementia in the NHS in England. Rather 
than short term, acute treatment, it is thought that antipsychotic use in people with dementia is 
more likely to be long term and rarely reviewed.43  
Initially, the increased mortality and CVAE risks were thought to be confined to the class of 
antipsychotic medications known as 'atypical antipsychotics'. As a result of the warnings, it was 
noted that there was an increase in prescribing 'typical antipsychotics' to elderly patients with 
dementia.44 Typical antipsychotics have a greater chance of negative side effects including over-
sedation, accelerated cognitive decline, extrapyramidal side-effects and tardive dyskinesia.45 Atypical 
antipsychotics have a slightly different side-effect profile, including: weight gain, disruption of blood 
glucose control, hyperlipidaemia and cerebrovascular adverse events, as well as sedation and 
                                                          
39
 We return to the application of the tort of negligence in part 3 below. 
40
 L Parnetti , S Amici, A Lanari, V Gallai  ‘Pharmacological treatment of non-cognitive disturbances in dementia 
disorders’ (2001) 122(16) Mechanisms of Ageing and Development 2063–2069. 
41
 NICE Dementia (n 5), 220. 
42
 Ibid, 237. 
43
 C Ballard, M L Hanney, M Theodoulou, S Douglas, R McShane, K Kossakowski, R Gill, E Juszczak, L Yu, R 
Jacoby ‘The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-
controlled trial’ (2009) 8 Lancet Neurology 151–57. 
44
 Royal College of Psychiatrists Faculty for the Psychiatry of Old Age ‘Atypical antipsychotics and behavioural 
and psychological symptoms of dementia: Prescribing update for old age psychiatrists’ (2004) available at: 
http://www.rcpsych.ac.uk/pdf/bpsd.pdf accessed on 02/03/2012. (RCPsych 2004) 
45
 Ibid, 3. 
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extrapyramidal side-effects at higher doses.46 Following this, the Committee for Medicinal Products 
for Human Use (CMHP) issued a report47 declaring that the risks associated with atypical 
antipsychotics were similarly applicable to the older class of antipsychotic medications known as 
‘typical antipsychotics’. On the basis of this report, it is now considered that the increased risks of 
stroke and death are a class effect relating to all antipsychotics when prescribed to elderly people 
with dementia. 
Reliable statistics relating to the prescription of antipsychotics to people with dementia are currently 
unavailable, as data on prescribing practices has not historically been recorded. An audit of 
prescribing practices in the NHS has recently been carried out, and suggests a reduction in the 
prescription of these medications in general practice over the last five years, though no figures are 
available for specialist prescription (e.g. by psychiatrists) or prescriptions in general hospitals.48 
Banerjee suggested that between 30 and 50 per cent of people with dementia in residential and 
nursing homes may be prescribed antipsychotic medication, and that:   
From the evidence available, it is clear that there are particular risks associated 
with the use of antipsychotics in people with dementia. Antipsychotics appear to 
be used all too often, in secondary as well as primary care, as a formulaic first-line 
response to any behavioural difficulty in dementia rather than as a considered 
second-line treatment when other approaches have failed. The data suggest that 
antipsychotics are used too often in dementia.49 
Given the risks of harm associated with the use of antipsychotics that have been identified in clinical 
research and practice, this level of off-label use is clearly unacceptable, particularly as the efficacy of 
antipsychotic medication to treat BPSD is not proven.50 The lack of evidence of efficacy may account 
for the limited number of antipsychotic medications that have, to date, been licensed for use in 
older people with dementia. There are significant costs to pharmaceutical companies of gathering 
the clinical trial evidence for efficacy and safety that would be required to obtain an MHRA license 
for treating BPSD with antipsychotic medication. Given the “high placebo response rates”51 reported 
for the use of medication to control BPSD, and the extensive off-label prescription,52 it is little 
wonder that there is limited will from the pharmaceutical industry to apply for licenses for these 
medications.  
                                                          
46
 Ibid. 
47
 CMHP Assessment Report on Conventional Antipsychotics (Procedure under Article 5(3) of Regulation (EC) 
No 726/2004. 
48
 ‘National Dementia and Antipsychotic Prescribing Audit’ available at 
http://www.ic.nhs.uk/services/national-clinical-audit-support-programme-ncasp/national-dementia-and-
antipsychotic-prescribing-audit accessed on 24 July 2012. 
49
 Banerjee (n 9), 30. 
50
 T Declercq, M Petrovic, R Vander Stichele, AIM De Sutter, ML van Driel, T Christiaens. ‘Withdrawal versus 
continuation of chronic antipsychotic drugs for behavioural and neuropsychiatric symptoms in elderly patients 
with dementia’ Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007726. 
51
 ibid. 
52
 The Alzheimer’s society estimate the per annum cost to the UK of antipsychotic medication in dementia is 
approximately £90 million. Alzheimer’s Society website ‘Facts on Antipsychotic Drugs’ available at 
http://alzheimers.org.uk/site/scripts/documents_info.php?documentID=535&pageNumber=3, accessed on 01 
March 2012. 
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In addition to the clinical harms outlined above, carers of people with dementia report a range of 
other, perhaps less drastic, but often equally upsetting harms associated with the off-label use of 
antipsychotic medication. In the next part, we turn to the findings from recent empirical research 
exploring the experiences that carers of people with dementia have of the regulation of health and 
social care. 
II: CARERS’ EXPERIENCE OF ANTIPSYCHOTIC MEDICATION 
A: Method and Participant Demographics 
The empirical data drawn on here were generated through a tripartite data collection process 
exploring carers’ experiences of access to, and the regulation of, health and social care support 
services for people with dementia. The findings are drawn from two inter-linked research projects, 
which included a multi-method online and paper questionnaire (n=185), followed up with four focus 
groups (n=15) and eleven in-depth interviews.53 Survey respondents were recruited through 
strategic opportunistic and snowball sampling via relevant charitable/third sector organizations 
including carers groups and support services. Paper recruitment packs were posted to a total of 461 
dementia and/or care-focused support groups run by the Alzheimer’s Society and the Princess Royal 
Trust for Carers. These paper packs were followed up a fortnight later with email reminders. 
Recruitment emails were sent to an additional 13 dementia-related organisations, and recruitment 
details were posted on four online discussion forums. The questionnaire was live for a period of four 
months, between February and May 2011. Carers could either complete the questionnaire online 
(n=154) or contact the research team for a postal questionnaire pack (n=31).  
Given the varied nature of the recruitment strategy, and our reliance on the goodwill of 
‘gatekeepers’, it is difficult to assess the response rate, though a basic calculation of number of 
completed questionnaires (185)/number of recruitment messages, emails and postal contacts (939), 
suggests a response rate of just under 20% overall. Participants in the focus groups and interviews 
were predominantly recruited from within the questionnaire responses. As this research is based on 
an opt-in, convenience sample, there are limited claims that can be made about the generalizability 
of the findings, though we do note where our findings are similar to those in previous research. 
Quantitative results from the survey were analysed using SPSS to find frequencies and differences 
between groups of respondents. Qualitative results from the focus groups and interviews were 
independently coded by the research team, using both deductive and inductive codes. Deductive 
codes were generated from the project research questions, inductive codes presented themselves as 
patterns within the data. 
Table 1 provides outline demographic information for questionnaire respondents, and the people 
they care for. The majority of respondents were women (n=128, 69.2%) caring for roughly equal 
numbers of men (87, 47%) and women (97, 52.5%). Respondents were overwhelmingly white 
(97.2%) and heterosexual (97.3%), with a mean age of 62.2 years. A majority identified their religion 
as Christian (n = 139, 75.1%). Most carers (n = 143, 77.3%) reported no disability, though just under a 
                                                          
53
 Most focus group and interview participants were recruited from respondents to the questionnaire. A total 
of 190 individuals participated in the research. 
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quarter (n = 42, 22.7%) reported having a disability, including: arthritis, cancer, diabetes and mobility 
impairment.  
Table 1: Questionnaire Demographics      
 
Carers 
  
People with dementia 
 Age Range Min Max Mean Min Max Mean 
Years 26 87 62.6 44 97 76.2 
 N %  N %  
Gender      
 Female 128 69.2 
 
97 52.5 
 Male 56 30.3 
 
87 47 
 Total54 184 99.5 
 
184 99.5 
 Race 
      White British 161 87 
 
157 84.9 
 White Irish 6 3.2 
 
7 3.8 
 White Other 13 7 
 
16 8.6 
 Mixed (White and Asian) 1 0.5 
 
2 1.1 
 Black African 1 0.5 
 
0 0 
 Asian Other 1 0.5 
 
0 0 
 Mixed (Other) 0 0 
 
1 0.5 
 Total 183 98.9 
 
183 98.9 
 Disability 
      Reported disability 42 22.7 
 
140 75.7 
 No disability 143 77.3 
 
45 24.3 
 Total 185 100 
 
185 100 
 Sexual Orientation 
      Heterosexual 180 97.3 
 
180 97.3 
 Bisexual 2 1.1 
 
0 0 
 Total 182 98.4 
 
180 97.3 
 Religion 
      No religion 37 20 
 
30 16.2 
 Christian 139 75.1 
 
149 80.5 
 Buddhist 2 1.1 
 
0 0 
 Jewish 2 1.1 
 
0 0 
 Muslim 1 0.5 
 
3 1.6 
 Other 3 1.6 
 
2 1.1 
 Total 185 100 
 
185 100 
 Self-defined Social Class 
      Middle Class 109 58.9 
 
100 54.1 
 Working Class 73 39.5 
 
77 41.6 
 Other 1 0.5 
    Total 183 98.9 
 
177 95.7 
  
                                                          
54
 Where totals do not add to n=185/100% this is due to missing responses 
 
 
10 
 
 
Fifteen participants attended four focus groups held in two large cities and two towns in central and 
southern England between September and December 2011. A total of 34 people were invited to 
participate in focus groups, and originally 18 carers had agreed to participate, but three were not 
able to attend on the day. The response rate for focus group participation was therefore 44%.  All 
Table 2: Focus Group Demographics 
Pseudonym Age Class 
Person care 
for/ age 
Type of 
dementia 
Residence 
of PWD 
Caring 
Status 
Chloe (FG1) 58 Middle class Mother, 84 
Vascular 
dementia 
Nursing 
home 
Ex-carer 
Laura (FG1) 55 Working class Father,  88 
Vascular 
dementia 
Nursing 
home 
Current 
Peter (FG1) 58 Working class Mother, 92 
Mixed: 
Alzheimer’s 
and Vascular 
Own home Current 
Viv (FG2) 64 Middle class Husband, 68 
Parkinson’s 
disease with 
Lewy Body 
Dementia 
Own home Current 
Morris (FG2) 78 Middle class Wife, 71 
Front-temporal 
dementia 
Own home Current 
James (FG2) 47 Middle class Mother, 77 
Vascular 
dementia 
Own home Ex-carer 
Sarah (FG2) 67 Middle class Husband, 70 
Fronto-
temporal 
dementia 
Own home Current 
Gwen (FG2) - Middle class Husband, - 
Lewy Body 
Dementia 
Nursing 
home 
Ex-carer 
Graham 
(FG3) 
87 Working class Wife, 86 Alzheimer’s Own home Current 
Angela (FG3) 67 Middle class Husband, 74 Alzheimer’s 
Nursing 
home 
Current 
Sandra (FG3) 62 Working class Husband, 80 
Vascular 
dementia 
Nursing 
home 
Current 
Jean (FG3) 72 Middle class Husband, 75 Alzheimer’s 
Nursing 
home 
Current 
Margaret 
(FG4) 
77 Middle class Husband, 81 
Vascular 
dementia 
Nursing 
home 
Current 
Tom (FG4) 73 Middle class Wife, 69 Alzheimer’s Own home Current 
Alan (FG4) 59 Working class Mother, 89 Alzheimer’s Own home Current 
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participants were white and heterosexual. In total 8 hours 40 minutes of focus data were collected, 
with each group lasting around 2 hours.  
As we can see from Table 2, nine (60%) of the participants were women, six (40%) were men and 
their mean age was 66 years (range 47-87). The majority (12, 80%) were currently caring and three 
participants were bereaved. Ten (67%) participants defined as middle class, while five (33%) defined 
as working class. Ten (67%) were caring for a spouse, while five (33%) were caring for a parent. The 
mean age of the person the participants cared for was 78.9 years (range 69-92) and they had been 
diagnosed with a range of dementias: five (33%) with Alzheimer’s disease; five (33%) with vascular 
dementia; two (13%) with Lewy Body dementia; two (13%) with fronto-temporal dementia and one 
with mixed Alzheimer’s and vascular dementia. About half of the people with dementia resided in 
their own home and half in a nursing home. 
Table 3: Interview Demographics 
Pseudonym Age Class Person care 
for/ age 
Dementia type Residence of 
PWD 
Caring 
status 
Victoria  63 Middle 
class 
Mother, 88 Alzheimer’s Own home Current 
Carlos and 
Anne 
58 Working 
class 
Father, 87 Alzheimer’s Own home Ex-carer 
Jan 58 Working 
class 
Mother, 87 Vascular 
dementia 
Residential home Current 
Emma 79 Middle 
class 
Husband, 83 Vascular 
dementia 
Residential home 
(self-funding) 
Current 
Sue 59 Working 
class 
Mother, 87 Vascular 
dementia 
Residential home 
(self-funding) 
Current 
Derek 65 Working 
class 
Mother, 86 Vascular 
dementia 
Own home Ex-carer 
Maureen 60 Middle 
class 
Mother, 95 Alzheimer’s Nursing home 
(self-funding)  
Ex-carer 
Kaylet 59 Working 
class 
Husband, 67 Fronto-temporal 
dementia 
Own home Current 
Jonathan 67 Middle 
class 
Wife, 66 Fronto-temporal 
dementia 
Nursing home 
(NHS continuing 
care) 
Current 
Mick 70 Working 
class 
Wife, 68 Alzheimer’s Nursing home 
(NHS continuing 
care) 
Current 
Pamela 56 Middle 
class 
Husband, 60 Fronto-temporal 
dementia 
Own home Current 
 
Table 3 provides demographic information about carers who were interviewed. Interviews ranged 
from 1 hour 16 minutes to 2 hours 7 minutes (mean length 1 hour 37 minutes) and were conducted 
in participants’ homes between November 2011 and January 2012. Most interviews were conducted 
in the Midlands, three were conducted in the North of England and two in the South. All participants 
were white and all identified as heterosexual apart from one bisexual woman.  Eighteen potential 
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interviewees were invited to participate, so the response rate was 61%, although only two carers 
who were contacted actively declined participation. Interviewees’ mean age was 63 years (range 56-
79) and the mean age of the person they cared for was 79.5 years (range 60-95). 
B: Statistical Findings – Antipsychotic medication 
In the questionnaire, 52 carers (28.1%) reported that the person with dementia that they care for 
had been prescribed antipsychotic medication. This proportion roughly corresponds with the 
proportion of people with dementia prescribed antipsychotics identified by Banerjee in his 
investigation into the prescription of antipsychotic medication to people with dementia.55 These 52 
carers reported 72 prescriptions of antipsychotic medication, as several (n=15, 8.1%) reported the 
prescription of more than one type of antipsychotic. Table 4 provides a breakdown of the 
antipsychotic prescriptions. Of the types of antipsychotic medication prescribed, Risperidone, which 
is the only antipsychotic drug licensed for use with people with dementia, accounted for just 15 
(21%) of these reported prescriptions. As such, up to 79% of the prescriptions of antipsychotic 
medications reported by respondents in this study may be ‘off-label’ prescriptions. 
Table 4: Reported Prescriptions of Antipsychotic Drugs 
Antipsychotic Medication No. Reported Prescriptions 
Amisulpride 4 
Quetiapine 29 
Risperidone 15 
Chlorpromazine 3 
Haloperidol 12 
Promazine 3 
Others 6 
 
A series of Chi-Square analyses were run to interrogate factors that may increase the likelihood of a 
person with dementia being prescribed antipsychotic medication. No significant differences were 
found in relation to the gender or self-identified social class of either the carer or the person with 
dementia, nor on whether the carer lived with the person with dementia. Three statistically 
significant differences were found in these data. Firstly, there was a significant association between 
the reported diagnosis, and the prescription of antipsychotic medications, with those with a 
diagnosis of frontotemporal dementia (FTD) (n=17, 41.5%) and Dementia with Lewy Bodies (DLB) 
(n=3, 50%) more likely to report such prescriptions than those with other diagnoses (𝑥2 = 21.313,
𝑑𝑓 = 8, 𝑝 = 0.006). This difference can be explained, at least in part, by the different sets of 
symptoms that people with these rarer forms of dementia experience. These forms of dementia 
often have significant behavioural components, including for FTD behavioural difficulties, and for 
DLB fluctuating cognitive disturbance.56 Importantly, however, the use of antipsychotic medication 
                                                          
55
 Banerjee (n 9). 
56
 NICE Dementia, (n 5), 30. 
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for DLB is explicitly contra-indicated in the NICE guidance, “because those with DLB are at particular 
risk of severe adverse reactions”.57 
The second statistically significant finding was that carers of people with dementia who reported the 
prescription of antipsychotic medication were significantly more likely (𝑥2 = 10.921, 𝑑𝑓 = 1, 𝑝 =
0.001) to report having had cause to complain (n=31, 65.3%) about the way the person they care for 
was treated by professionals than those who did not report the prescription of antipsychotic drugs 
(n=49, 37.1%).  Finally, and perhaps most interestingly, there was also a significant association 
between observed and expected frequencies for antipsychotics prescribed to people with dementia 
living in formal residential or nursing care (𝑥2 = 5.344, 𝑑𝑓 = 1, 𝑝 = 0.021). Carers of people with 
dementia living in formal care were therefore statistically significantly more likely to report that the 
person they care for had been prescribed antipsychotic medication. If we look solely at those people 
with dementia living in formal care (n=39, 22% of total respondents), the proportion of people with 
dementia prescribed antipsychotic medications increases to nearly one half of these (n= 17, 43.6 %). 
There are likely to be a number of factors that contribute to this finding, including that BPSD are 
factors in carer strain,58 and in the early institutionalisation of people with dementia.59 These are, 
however, statistically significant differences, which echo findings from previous research exploring 
these issues.60 These statistical findings can be interrogated further by exploring the qualitative data 
from carers in the questionnaire, focus groups and interviews. 
C: Qualitative Findings – Carers experiences of antipsychotic medication 
Alongside these three statistical findings, the qualitative comments highlight three themes in respect 
of carers’ experience of the use of antipsychotic drugs in people with dementia. Firstly, carers 
document the negative effects on people with dementia from the use of this class of medication. 
Second, they spoke of their own interventions to reduce or prevent the prescription of 
antipsychotics to the person they care for, including removing the person with dementia from in-
patient or respite care in order to protect them from the prescription of antipsychotic medication. 
Finally, some respondents spoke of alternatives to antipsychotic medication for the treatment of 
BPSD. 
Whilst only one participant spoke of what would be described in the clinical literature as a severe 
adverse effect: “my husband was so poorly following several near death experiences with 
antipsychotics” [Quest_92],61 a variety of other harms were described by these participants. Many 
participants highlighted the sedative effects of these medications, for example: 
                                                          
57
 NICE Dementia, (n 5), 35. 
58
 Thomson et al, (n 7). 
59
 Banerjee et al, (n 8).  
60
 E.g., Banerjee (n 9); Banerjee et al, (n 8). 
61
 Each qualitative excerpt is labelled with the method of collection and a unique identifier for the participant. 
[Quest_92] thus refers to questionnaire response ID 92. [FG2_Viv] would refer to a participant with the 
pseudonym ‘Viv’, who participated in Focus Group 2. Similarly, [Int_Kaylet] refers to the interviewee with the 
pseudonym ‘Kaylet’. All names used are pseudonyms and any potentially identifying information has been 
changed. 
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My Mother…was given antipsychotic drugs that turned her into a zombie. 
[Quest_ 62] 
I was strongly against the use of this drug [Seroquel] after it left my dad in a 
zombie state [Quest_88] 
He was, at one point, very much like a zombie because of the antipsychotic drugs 
he was on because he’d been violent. [FG3_Angela] 
They put her on these antipsychotic meds, which I’ve looked up on the internet 
and they are- I think they’re being withdrawn now. They made her catatonic, 
basically. [Int5_Sue] 
Clearly, carers find the sedative effects of antipsychotic medication distressing and unhelpful. 
Perhaps more importantly, these carers’ experiences highlight that the use of antipsychotic 
medication as a means of controlling behaviour can be experienced as harmful even in the absence 
of “severe” side effects. Several carers attributed the prescription of antipsychotics to a lack of 
knowledge, training or awareness of the negative effects on people with dementia. Consider this 
quote from a questionnaire respondent: 
I did speak with Dr [name] about the drug he'd prescribed he said it was for my 
dad's depression (my dad has never suffered from depression) after researching 
online about this drug I went to my dad's doctor and strongly requested that my 
dad came off this drug as it had a black box warning and should not be used as it 
was for Bi-polar disorders - it stated that it should not be given to people over 65 
suffering from dementia and heart problems - it was given to my dad as a 
suppressant - I was angry that this drug was given to my dad in the first place. I 
think some doctors and nursing staff have very little knowledge if any about 
caring for dementia people. [Quest_88] 
In this excerpt, a woman (55) who provides most of the day-to-day care for her father (78) and for 
whom she has financial Power of Attorney (PoA),62 describes an instance of the prescription of 
Seroquel.63 She describes her use of the Internet to find out about the medication her father had 
been prescribed. It is clear from the way that she tells this story that not only had the prescription 
been ‘off-label’, but also that the possible adverse effects had not been discussed with her, as her 
father’s carer. Whilst it is possible that her father had capacity to consent to this treatment at the 
relevant time, if he did not have capacity, then the prescriber has a duty to follow the best interests 
test in the Mental Capacity Act 2005 (MCA). Under the MCA, before a health professional can 
prescribe medication to a person who lacks the capacity to consent, they must firstly determine that 
                                                          
62
 In the survey we asked respondents whether they had financial power of attorney, welfare power of 
attorney or had been appointed as a deputy by the Court of Protection, rather than using the lasting power of 
attorney/enduring power of attorney distinction. Many respondents who had been caring for several years did 
not have the (newer) welfare power of attorney. 
63
 Generic name quetiapine 
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it is in that person’s best interests to do so. As part of the best interests determination, they must, 
where “practicable and appropriate” consult with and take into account the views of anyone 
engaged in caring for the person,64 or any “donee of a lasting power of attorney”.65 As antipsychotic 
medication has a sedative effect, it is also important to consider the possibility that such a 
prescription may amount to restraint,66 and could be potentially be considered to amount to a 
deprivation of liberty under Article 5(1) of the European Convention on Human Rights (ECHR) if “the 
health care professionals treating and managing the [patient] exercised complete and effective 
control over his care and movements.”67 In cases where there is a possibility of the deprivation of 
liberty,68 then the Deprivation of Liberty Safeguards (DOLS)69 procedures must be followed.        
Mick,70 who was interviewed for the Dementia Talking project, also spoke of his experience of 
looking up symptoms on the internet: 
Well I mean Kate was leaning over to side and one of things they were saying was 
er, she were constipated. I said “She certainly isn’t constipated cos I’ve been 
there when they changed her pads.” So I put this leaning into Alzheimer’s website 
and it come up with nothing. Got onto Alzheimer’s Association and they call it 
Pisa Syndrome. They’ve had it documented for ages. Put it down purely to drugs. 
So care home, well it were nursing home, that Kate was in at that time, I told GP 
about drugs, she said “Well I shouldn’t touch her drugs, but seeing”- they’d just 
put her on, I forget what it were called, just put her on this drug. […] Anyway the- 
this doctor rung care home up and said “How’s she doing?” She said “Oh she’s 
still-” she were getting a bit agitated again, you know, and er so they doubled this 
drug. Well she started leaning more and falling, actually falling. So I told GP, and 
she said “Well I’ll cut her back to what she was on on original dose.” Well she 
straightened up in two days, and then it wasn’t long they took her off it 
completely. [Int_Mick] 
Clearly Mick found relevant information online that allowed him to negotiate with the GP, and 
question the particular prescription that had been given to his wife. He then attributes his 
intervention to the reduction in dose, lessening of the drug-induced dystonia his wife was suffering 
from and subsequent withdrawal of the medication. Several carers in our study described having to 
intervene when medication that they thought was inappropriate for the person they care for was 
prescribed:  
                                                          
64
 MCA 2005, s. 4(7)(b). 
65
 ibid, s. 4(7)(c) 
66
 MCA 2005, s.6. 
67
 HL v. The United Kingdom (Application no, 45508/99), at para 91. 
68
 Note that the UK courts have recently taken a fairly restrictive approach to the definition of deprivation of 
liberty, particularly in respect of persons living at home or in a care home: Surrey County Council v. CA and LA 
and MIG and MEG [2010] EWCA Civ 190. 
69
 MCA 2005, s4A and Schedule A1, as inserted by the Mental Health Act 2007, s. 50.  
70
 See table 3 above. 
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I was appalled at the use of anti-psychotic drugs (once I realised what they were 
and after I took my husband off them) in the general hospital given by medical 
staff who did not seem to realise their effect on someone with dementia. He was 
up all night and extremely confused and then slept by day once I visited him and 
enabled him to rest. I stayed up all one night once he was home to document 
their effect on my husband and then gradually took him off them.  They are EVIL! 
… They make people worse not better and they kept increasing the dose to try 
and make him more 'manageable'. They failed. [Quest_ 119] 
Again, in this account from a woman (62) caring for her husband (72), who reported the prescription 
of two different types of antipsychotic medication (quetiapine and haloperidol), there is another 
instance of carers clearly not being provided with full information about the off-label prescription of 
antipsychotic drugs (“once I realised what they were”). Here, she weaned her husband off the 
medication once he was home from hospital. For other carers, the prescription of antipsychotic 
drugs resulted in them removing their family member from formal care provision.  
Another occasion he went to a unit for assessment which was totally lacking in 
dementia care, he was drugged and put in a nappy when he had no continence 
problems, he fell and sustained a head injury as a result of this so next night he 
was put on the floor on a mattress. When I visited the staff supposedly caring for 
him were sitting watching TV while he was wandering up and down in a dazed 
state and when I removed him the staff became very defensive and I 
subsequently found that this was not an isolated incident. [Quest_63] 
Here, this woman (62), who cared for her husband (now deceased), who was also prescribed 
quetiapine, describes a significant failure of care, which resulted in her removing him from the 
assessment unit prematurely. The way she describes his treatment “he was drugged and put in a 
nappy” suggests that the treatment he received may have been inappropriate, and was unlikely to 
have been in his best interests. There may even be some possibility of interference with his rights 
under the inhumane or degrading treatment branch of Article 3 ECHR. Many carers articulated very 
strong feelings about the inappropriateness of the prescription of antipsychotic medication. In a 
focus group, Tom71 shared an experience from when his wife had been in respite care while he 
underwent major surgery: 
During the sixth week [of respite] she started having nightmares, and so they 
wanted to give her antipsychotics, and I said ‘no’.  But the doctor actually 
prescribed them, and I think she was given one tablet and it gave her the runs, 
and they didn't give her anymore.  But as soon as they said that, I- although I 
wasn't fit enough to bring her home, I brought her home. [FG4_Tom] 
Similarly, in an interview, Sue described removing her mother from in-patient care because of the 
effects of antipsychotic medication: 
                                                          
71
 For more demographic information, see Table 2, above. 
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They made her catatonic, basically, she was- So we took her out … we discharged 
her and we took her home and she said “oh thank God I’m home.” And she told 
me all about what had happened in hospital and how she’d had a fall 
unsupervised, she’d been unsupervised and gone to the toilet and had a fall. And 
black and blue, they made her sign a disclaimer. She told me about that. We 
didn’t know about that. She said “they made me sign a form saying, you know, I’d 
been offered help and I didn’t want”...something like that.  [Int5_Sue]  
In all three of these excerpts the familial carer describes removing the person with dementia from 
formal care, in an assessment unit, a respite care home and hospital respectively, because they 
experienced failures of care associated with the prescription of antipsychotic medication. This 
highlights the ways that the potential harms associated with the use of antipsychotic drugs to 
control BPSD are not limited to biochemical side effects of the medication (e.g. stroke, death) but 
also include over-sedation and exacerbation of behavioural problems, which require additional input 
from carers. Without such additional support, the antipsychotics can lead to the person with 
dementia experiencing physical injuries, falls, and heightened confusion.  
Viv, whose husband has a complex diagnosis of a rarer type of dementia, and who can exhibit “very 
aggressive, challenging behavior” spoke of her conversation with her husband’s neurologist: 
The neurologist wants to prescribe, um, antipsychotic drugs, which are now being 
debated as being-you shouldn’t do that, you know. So the last time we went to 
the neurologist at [the hospital] he said ‘are you using Seroquel?’ I said, ‘well, 
honestly, doctor, I prefer not to use Seroquel’, I mean it’s a real chemical cosh, 
you know, ah, and it makes him very weird. I mean, he’s very weird anyway, but 
the Seroquel, the chemical cosh makes him, sort of, doubly bad. [FG2_Viv]  
This mirrors findings from previous qualitative research with old age psychiatrists about why they 
prescribe antipsychotic medication to control BPSD. 72  Wood-Mitchell et al found that “psychiatrists 
often felt pressured to ‘do something’ and believed that in many cases non-pharmacological 
approaches were not feasible due to a lack of resources, time constraints and difficulties in 
implementation.”73 This is in contrast to the NICE guidance which suggests that all other approaches 
to control challenging behaviour should be attempted prior to the prescription of antipsychotics.74 
Another focus group participant, Angela, spoke of her concerns that her husband would be 
prescribed antipsychotics again because of his behaviour: 
Over the last weekend he’s actually hit one of the nurses again.  So now, of 
course they- they don’t know why it’s suddenly flared up, … he might be in pain, 
and he can’t communicate that and so that may- may be what’s making him 
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 A Wood-Mitchell, I A James, A Waterworth, A Swann and C Ballard ‘Factors influencing the prescribing of 
medications by old age psychiatrists for behavioural and psychological symptoms of dementia: a qualitative 
study’ (2008) 37(5) Age & Ageing 547-552. 
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 Ibid, 551. 
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frustrated and therefore he lashes out.  That was waiting for me on Friday when 
we got home so, you know, it, I- I- I will say I don’t want him to go back on the 
antipsychotic because it made him such a zombie but [sighs] it may be a 
possibility that we have to face. [FG3_Angela] 
Here, it seems that Angela directly links the use of antipsychotic medication to be the possible 
response to a single incident. She also describes other causes for this challenging behaviour, such as 
pain and the inability to communicate, or frustration. Just before the above excerpt, Angela said that 
her husband has been taking memantine,75 which is not an antipsychotic medication but is used to 
treat dementia, and which has helped to control his challenging behaviour over several months. 
Similarly, Mick described his experience with memantine: 
She were in a care home and they kept calling it violence and I thought it was 
more agitation than violence...Anyway, we were mentioning it to doctor one time 
and I said “What about this Memantine?” “I don’t think it’ll work for Kate.” I said 
“You don’t think it’ll work or you- you know it won’t work?” He said “I don’t think 
it’ll work.” Well deal was that we tried it for three months see how she went on, 
and it calmed her down. I mean even when doctor came in after three months, 
even carers were dashing up and telling him she were a lot better, you know, and 
in fact she’s still on Memantine. That would be- she’s probably been on 
Memantine two years. [Int10_Mick]  
Memantine is one of the four medications licensed for treatment of the cognitive symptoms of 
dementia. Memantine is specifically licensed for use in people with moderate to severe Alzheimer’s 
disease, and following the most recent NICE-SCIE Dementia Guideline, can be prescribed for the 
treatment of cognitive symptoms of moderate to severe Alzheimer’s disease,76 and “some 
behavioural effects have been noted.”77 Importantly, therefore, there are other medications that 
have been proven to help with reducing challenging behaviour in people with dementia. Consider 
also this excerpt from Tom, during a discussion about antipsychotic medication: 
As I say, there must be cases where it's appropriate, but most aren't.  And 
paracetamol, I know a case where it's worked wonders. [FG4_Tom] 
Here, Tom is referring to research published by the BMJ in 2011 that found a significant reduction in 
agitation in people with dementia on a number of measures following an eight-week treatment 
intervention with analgesics.78 Findings from research such as this may signal a move away from the 
use of antipsychotic medication as a first line response to BPSD. Importantly, however, as well as the 
possibility of prescribing analgesics or memantine to treat BPSD, the increased attention given to 
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 NICE Dementia, (n 5), 95. 
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antipsychotics may lead to an increase in the prescription other forms of medication, including the 
off-label prescription of other neuroleptic drugs that also have a sedative effect, and negative side 
effects.79  
In summary, the qualitative findings from these research projects highlight that carers 
overwhelmingly report negative experiences of the prescription of antipsychotic medication to 
people with dementia.80 In contrast to the severe adverse effects (e.g., stroke, death) of these drugs 
highlighted in clinical research, carers described a range of other harms experienced by the person 
with dementia that they care for. They described sedative effects of antipsychotics, leaving people 
with dementia like ‘zombies’ or ‘catatonic’. Informal carers, including those with power of attorney, 
reported not being consulted prior to the use of antipsychotic medication nor given any information 
about the risk/benefit profile of the drugs prescribed. Several carers reported removing people with 
dementia from formal care settings because of failures of care associated with the prescription of 
antipsychotics. Finally, some carers spoke of health care professionals’ reluctance to prescribe other 
medication that may help with the behavioural issues that were experienced by the people with 
dementia that they cared for, in spite of evidence that these alternatives may be effective. All of this 
qualitative evidence works together with the statistical findings outlined above to provide an 
overview of carers’ experiences of the use of antipsychotic medication in people with dementia. In 
particular, the experiences recounted by carers provide ample evidence of why carers who had 
reported the prescription of antipsychotic medication reported higher levels of ‘cause to complain’.  
In the next part, we draw together the regulatory framework for off-label prescription, the 
documented risks of serious adverse effects from the off-label prescription of antipsychotic 
medication, and carers’ experiences of this in practice to explore the legal options for individual 
redress for harm, and the potential for regulatory reform in respect of off-label prescription. Before 
exploring the particular legal issues associated with off-label prescribing practices, it is essential to 
be clear that the flexibility to prescribe medicines off-label is an essential part of medical practice, 
and our aim in this article is not to argue for this flexibility to be withdrawn from medical 
professionals. Rather, our argument is that because there is a potentially higher risk of harm to 
patients from off-label prescription, it should be subject to greater regulatory control, and that there 
should be redress available where a patient is harmed as a result of off-label prescription.81 
III: LEGAL REDRESS FOR HARM FROM OFF-LABEL PRESCRIPTION OF 
ANTIPSYCHOTICS IN DEMENTIA CARE 
The system for licensing medications described in part one has the primary aim of protecting and 
promoting public health. Where medications are prescribed or supplied in accordance with their 
marketing authorisation, there are a number of avenues for redress available to a consumer who is 
harmed by using the medication. The most straightforward of these is the products liability regime. 
                                                          
79
 Including benzodiazepines, hypnotics, anticonvulsants and antidepressants – see Banerjee, (n 9). 
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 Eisai v NICE [2007] EWHC 1941 provides an interesting discussion of whether benefits or detriments to 
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Under the Consumer Protection Act 1987 (CPA), a consumer is entitled to a remedy where the safety 
of a product (including medicines) is "not such as persons generally are entitled to expect."82 This 
product liability regime is a strict liability compensation regime, and where, for example, there is a 
manufacturing defect in a medication prescribed in accordance with its marketing authorisation, 
there would be a clear route to redress. Conversely, where a medication is prescribed off-label, it 
would extremely difficult to claim that any adverse effects amounted to a defect in the medication 
(particularly if such adverse effects were documented, as is the case with antipsychotic medications 
and dementia). Potential claims under the CPA are also subject to a ten year time limit from the date 
a product is first marketed, 83  which would also rule out claims in respect of many typical and 
atypical antipsychotic drugs. The CPA is therefore unlikely to prove a fruitful avenue for redress for 
people with dementia who suffer adverse effects from the off-label prescription of antipsychotics. 
A second route to redress for a person who purchases general sale list medicines, pharmacy 
medicines, or prescription-only medications on a private prescription would be through the ordinary 
contractual remedies that apply to consumers. So, for example, a remedy through the Sale of Goods 
Act 1979 may be available to a consumer where the medicine did not correspond with its description 
or is not of satisfactory quality.84 Where medications are prescribed on the NHS, however, there is 
no sale, and therefore there would be no route to redress through the law of contract,85 irrespective 
of whether a medication is prescribed as per the marketing authorisation or off-label. Given that 
these two routes to redress from the manufacturer and from the vendor of medications are 
therefore unavailable to people with dementia harmed by the prescription of antipsychotic 
medications off-label on the NHS, the only remaining avenue for redress is that provided by the tort 
of negligence.  
There are two possible approaches that could form the basis of a cause of action for a person with 
dementia harmed by the prescription of antipsychotic medication: first, if they were not adequately 
consulted about the possible risks, they could argue that, following Chester v Afshar86 the prescriber 
did not sufficiently discharge their duty to warn of the risks. Second, they could argue, that the off-
label prescription of antipsychotic medication fell below the standard of care required of a medical 
professional. We discuss each of these examples in turn. 
A: Failure to Warn of Risks as Breach of Duty 
One approach that may be available to a person with dementia harmed by the off-label prescription 
of antipsychotics would be, following Chester v Afshar87, that the relevant breach of duty was the 
failure to warn of the risks associated with the prescription of this type of medication. The relevant 
rule of law is that a patient has a right to be told if there is “a significant risk that would affect the 
judgment of the reasonable patient” 88  in order to give her informed consent to the treatment. In 
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Chester v Afshar,89 the risk in question was a 1-2% chance of paralysis following neurosurgery. In the 
situation we are concerned with here, the risks in question would include the increased risk of 
severe adverse effects including stroke, and death, as well as the more ‘minor’ risks of over-
sedation, falls, accelerated cognitive decline and tardive dyskinesia. 
The source of this right to be warned of the risks inherent in medical treatment has been said to lie 
with the individual right to autonomy, and more specifically, the right of a patient to decide whether 
or not to undergo treatment. As Lord Steyn put it: “in modern law medical paternalism no longer 
rules and a patient has a prima facie right to be informed by a surgeon of a small, but well 
established, risk of serious injury as a result of surgery.”90 In ordinary circumstances, therefore, a 
medical professional who prescribed a drug that carried a risk of serious side effects, without first 
warning the patient of those side effects would lay himself open to a claim in negligence for breach 
of his duty to warn of significant risks. Inevitably, because we are focusing on the treatment of 
people with dementia, the issue of failure to warn of risks will often be more complex, because the 
question of capacity to consent to treatment will often arise.  
Under the MCA, everyone who has the capacity to make their own decisions must be supported to 
do so.91 Where a person lacks the capacity92 to make a decision,93 then any decisions made on behalf 
of that person must be in their best interests.94 The MCA effectively translated the common law best 
interest tests95 into legislative form. Statute now requires that where a doctor treats a patient who 
lacks the capacity to consent in their best interests, they must consider “the person’s past and 
present wishes and feelings (and, in particular, and relevant written statement made by him when 
he had capacity)”96  as well as the views of any named consultees, carers, anyone with Power of 
Attorney, or who has been appointed as a deputy.97 The English courts have not yet, to our 
knowledge, had the opportunity to determine how this duty to warn of the risks of a particular 
course of medical treatment would interact with the best interests test in the MCA.  
It is possible that a breach of this duty would arise if a person with dementia was treated with an off-
label prescription of antipsychotic drugs at a time when she lacked the capacity to consent to such 
treatment, and if neither she nor her carer (or any relevant deputy or attorney) were warned of the 
risks of stroke and death. However, given the MCA requirement prior to treatment in the best 
interests of an incapacitated patient is simply to consult with carers, deputies or attorneys, and to 
consider the previous wishes of the patient, it may be difficult to establish a breach of duty.98 This is 
because “there is sufficient compliance with this section if…he reasonably believes that what he 
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does or decides is in the best interests of the person concerned.”99 Importantly, however, even if a 
breach of duty were established, following this line of reasoning, the claimant would still need to 
prove that the harm was caused by the failure to warn of the risks, rather than the prescription of 
the medication itself. In other words, they would need to successfully argue that had they been 
warned of the risks they would not have consented to, or would have objected to the treatment 
being administered, and that this would have prevented the medication being prescribed or 
administered. On balance, we consider it unlikely that a claim along these lines would have 
significant success, given the prevalence of the use of antipsychotic medication in treating BPSD. 
B: Prescription of Antipsychotics as Breach of Duty 
An alternative argument would be that the off-label prescription of antipsychotic medication per se 
fell below the required standard of care. The development of the concept of standard of care in 
medical negligence since Bolam has been the subject of extensive attention from legal scholars, and 
there is not space to rehearse these arguments here.100 In particular there has been a feeling that 
the courts have been, at times, been excessively deferential to the medical profession101 in 
determining whether a particular treatment regime or course of action was negligent. As such, given 
that the prescription of antipsychotics to control BPSD has been commonplace for a considerable 
period of time (in spite of the established risks and potential harms outlined above) it is unlikely that 
on application of the Bolam test alone, a person with dementia would succeed with an argument 
that the treatment fell below the standard of care required.  
There are two relatively recent developments that may increase the potential for success in a case of 
harm caused by antipsychotics prescribed for BPSD: first, the effect of Lord Browne-Wilkinson's 
reasoning in Bolitho,102 and second, the contemporaneous rise of the use of guidelines in medical 
practice. In the decade and a half or so since the decision in Bolitho, it has become apparent that its 
impact has been relatively modest.103 The facts of Bolitho have been well-rehearsed in the literature, 
but in brief, this case concerned a claim of negligence in respect of a two-year-old child with 
respiratory failure. The child suffered brain damage, and claimed that this was caused by the 
negligence of a doctor in firstly failing to attend, and secondly failing to intubate. The doctor claimed 
that even if she had attended, she would not have intubated and thus the case failed on the issue of 
causation.104 More importantly, for the present discussion, however is the now famous dicta of Lord 
Browne Wilkinson, revising the Bolam test to the extent that the court is able to disregard expert 
medical evidence that does not withstand logical analysis: 
In the vast majority of cases the fact that distinguished experts in the field are of 
a particular opinion will demonstrate the reasonableness of that opinion. In 
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particular, where there are questions of assessment of the relative risks and 
benefits of adopting a particular medical practice, a reasonable view necessarily 
presupposes that the relative risks and benefits have been weighted by the 
experts in forming their opinions. But if, in a rare case, it can be demonstrated 
that the professional opinion is not capable of withstanding logical analysis, the 
judge is entitled to hold that the body of opinion is not reasonable or 
responsible.105 
In Bolitho, on the facts, the court did not determine that there had been negligence, nor that the 
expert professional opinion was not capable of withstanding logical analysis. The court determined, 
rather, that the negligence in the case was the doctor's failure to attend, not the failure to intubate. 
Importantly though, the decision in Bolitho was to certain extents a restatement of a principle from 
a much older case, Hucks v Cole,106 decided in 1954, and reported in 1993. In this case, a pregnant 
woman was suffering from an infection, which was inadequately treated, and could have been easily 
resolved with a course of penicillin. She subsequently became seriously ill with puerperal fever. 
Medical experts on behalf of the defendant agreed they would have done the same thing, but the 
court found the doctor negligent: "When the evidence shows that a lacuna in professional practice 
exists by which risks of grave danger are knowingly taken, then, however small the risks, the court 
must anxiously examine that lacuna - particularly if the risks can be easily and inexpensively 
avoided."107 The reasoning in Hucks v Cole does seem to offer scope for the development of an 
argument about the relative seriousness of the risks associated with the prescription of 
antipsychotics to people with dementia (including death, stroke, interference with human rights, 
over-sedation etc) as compared to the limited evidence of benefit of prescribing these drugs (e.g., 
high placebo effect in clinical trials). It is possible, therefore, that the Bolitho formulation of the 
Bolam test may offer an avenue for a test case exploring negligence liability in respect of the off-
label prescription of antipsychotic medication.  
C: The Role of Clinical Guidance in Prescribing Antipsychotics for BPSD 
In order to assess whether there would be a likelihood of success in either of these types of claim, it 
is important to evaluate whether ‘the respectable body of professional opinion’ that supports the 
use of antipsychotic medication in BPSD is capable of ‘withstanding logical analysis’. Given the rise of 
the use of guidelines in medical practice, and the increasing likelihood of the use of these by lawyers 
in medical negligence claims,108 it seems appropriate to explore the relevant clinical guidelines that 
cover the treatment of BPSD.  
There are two sets of UK clinical guidelines that would be relevant to determining the appropriate 
standard of care for using pharmacological treatments in the management of challenging behaviour 
in dementia, the NICE/SCIE Guideline on Dementia109 and the Royal College of Psychiatrists Faculty 
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of Old Age Psychiatrists Guidance (RCPsych Guidance).110 The NICE/SCIE guideline was first published 
in 2006 (updated in 2011) and represents a comprehensive overview of the “identification, 
treatment and care of people with dementia and the support that should be provided for carers 
within primary and secondary healthcare, and social care.”111 In contrast, the relevant RCPsych 
Guidance was issued in 2005, has the issue of management of BPSD as its focus, and does not 
appear to have been updated in the intervening period. Both documents offer guidance on the 
prescription of antipsychotic medication for the treatment of BPSD.  
Importantly, in the context of evaluating the use of guidelines in medical negligence claims, there 
are some significant differences in the guidance issued to practitioners in each of these documents. 
In respect of treating “mild to moderate non-cognitive symptoms” the NICE/SCIE guideline has a 
much less permissive approach to the issue than the RCPsych document. The NICE guideline states:  
1.7.2.2 People with Alzheimer’s disease, vascular dementia or mixed dementias 
with mild-to-moderate non-cognitive symptoms should not be prescribed 
antipsychotic drugs because of the possible increased risk of cerebrovascular 
adverse events and death. 112 
In contrast, the RCPsych guidance suggests that it is appropriate to use antipsychotic medication as a 
first-line approach, even in respect of mild or moderate symptoms: 
Drugs may be an appropriate first response to BPSD symptoms in the following 
situations: where drugs have a specific indication (e.g. depression or psychosis), 
whatever the severity and frequency of the symptom…For less severe BPSD and 
where management is not urgent then any combination of drug, environmental 
manipulation or behavioural treatments may be appropriate first-line 
approaches.113 
The disparity in the guidance relating to severe symptoms is similarly interesting. NICE/SCIE guidance 
states: 
1.7.2.4 People with Alzheimer’s disease, vascular dementia, mixed dementias or 
DLB with severe non-cognitive symptoms (psychosis and/or agitated behaviour 
causing significant distress) may be offered treatment with an antipsychotic drug 
after the following [eight] conditions have been met.114 
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The eight conditions for prescribing antipsychotic medication include “full discussion with the person 
with dementia and/or carers about the possible benefits and risks of treatment. In particular, 
cerebrovascular risk factors should be assessed and the possible increased risk of stroke/transient 
ischaemic attack and possible adverse effects on cognition discussed”, as well as guidance about 
recording, individual risk-benefit analysis and regular reviewing of the medication.  
The RCPsych guidance, in contrast, states: 
Drugs may be an appropriate first response to BPSD symptoms…where the 
problem symptom is severe and treatment is needed quickly, for example if the 
target symptoms are severe (i.e. dangerous or distressing to the patient or 
others) and the behaviours have no clear situational trigger or occur in a setting 
where carers cannot cope with serious behaviour problems. 115 
The RCPsych guidance does not require the same level of consultation with the person with 
dementia or their carer about the risks of adverse effects as are set out in the NICE/SCIE document. 
Rather, the RCPsych guideline states: 
If the patient has the capacity to understand these risks and benefits of 
treatment approaches, then consent to treatment should be sought. If the 
patient does not have this capacity, then these risks and benefits should, where 
practical, be discussed and communicated to the general practitioner, relatives 
and carers. Ultimately the clinician has the responsibility for the decision to 
implement treatment. Relatives cannot consent on behalf of their incapacitated 
relatives. The relevant mental capacity legislation needs to be considered.116 
Leaving aside the somewhat concerning lack of engagement with either the specifics of the best 
interests test that should be followed when instigating treatment in respect of persons who lack 
capacity, nor the duty to warn of the risks associated with any medical treatment,117 there is clearly a 
difference in tone between these two sets of guidance. For the purposes of a medical negligence 
claim, both could be argued to set out a ‘responsible body of medical opinion.’ In a recent 
questionnaire study118 with members of the RCPsych Faculty of Old Age Psychiatrists suggests that 
medical professionals are more sympathetic to the guidance issued by their own professional 
association than guidance issued by NICE. In their study, Haw et al found that all 207 old age 
psychiatrists who responded to the survey said that they prescribed antipsychotics to patients 
experiencing BSPD, most commonly prescribing quetiapine, haloperidol or risperidone.119 Haw et al 
found that “two-thirds of respondents thought the NICE guideline on dementia was too restrictive, 
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whereas over three-quarters felt the RCPsych 2005 guidance supported psychiatrists in prescribing 
these drugs to individuals with dementia.”120 
Given the disparity between the two sets of guidance, it is probable that any negligence claim 
concerning the prescription of antipsychotic medication would therefore rest on whether the 
relevant body of professional opinion could, following Bolitho, “withstand logical analysis”.121 There 
has been (perhaps surprisingly) very little medical negligence case law since Bolitho that has been 
instructive on how this phrase could be interpreted. 122 Those that have been decided on what 
appears to be Bolitho principles have, of course, been based on the specific circumstances of the 
case in question, rather than laying down precedent as they are determinations of deviation from 
the relevant standard of care.123 Two cases where the courts have been willing to go against the 
testimony of expert witnesses as to the responsible body of medical opinion are Reynolds v North 
Tyneside Health Authority124 and Marriott v West Midlands Regional Health Authority.125 In both of 
these cases, the rarity of such a finding was stressed by the judge. In Reynolds, Gross J stated that 
“given the need for clinical judgment in areas such as medicine or midwifery, it is likely to be only in 
a rare case that the Court will regard it as appropriate to conclude that views genuinely held by a 
competent expert in the discipline in question are not capable of withstanding logical analysis and 
are hence unreasonable.”126 Given the findings from Haw et al, there would be no shortage of 
psychiatrists willing to provide expert testimony that the RCPsych guidance represents a responsible 
body of professional opinion. As there is one antipsychotic medication licensed for the treatment of 
BPSD, it would be extremely difficult to argue that the (admittedly serious) risks of prescribing this 
type of medication always outweighed any benefits, or even that the risks outweighed the potential 
benefits in any particular case. Taken together, it is therefore unlikely that a person with dementia 
would have much chance of bringing a successful claim under the tort of negligence, even with the 
extended Bolitho interpretation of the Bolam test, and with the increased reliance on clinical 
guidance in medical negligence cases. 
IV: CONCLUSIONS - INCREASED REGULATION OF OFF-LABEL PRESCRIPTION 
It is clear from the analysis in part 3 that current legal frameworks offer little chance of redress to a 
person with dementia harmed by the prescription of antipsychotic medication. Claims under 
statutory frameworks such as the Consumer Protection Act 1987 or the Sale of Goods Act 1979 
would fail, and medical negligence claims would be unlikely to succeed. Given the magnitude of 
harm experienced by people with dementia when these medications are prescribed, as 
demonstrated above, we argue that there is a strong argument for increased regulation of the 
prescription of these medications to people with dementia. In this final part, we set out why we 
think that the best way to regulate the over-prescription of antipsychotic medication would be to 
introduce controls on the off-label prescription of all pharmaceutical products. We argue that 
controls on off-label prescription should include: 1) the recording of evidence that a discussion has 
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taken place between the prescriber and the patient or their representative that a) the drug in 
question is not licensed for the use it is being put, and b) the risk/benefit profile of the off-label use 
of that medication; 2) a written record of a review framework for the prescription, including written 
records of reviews when they are undertaken; 3) explicit reference to any clinical guidance that 
permits or recommends the off-label use; 4) formalised frameworks for recording adverse effects 
(similar to the Black Triangle scheme currently used for new medications); and 5) clear routes to 
redress for patients or their representatives harmed by drugs that are prescribed off-label, or where 
the procedure has not been followed. 
In his report into the prescription of antipsychotic medication, Banerjee advised against the 
wholesale outlawing of antipsychotics for the treatment of people with dementia, preferring instead 
to recommend a voluntary reduction in prescriptions (by two-thirds) as a clinical governance 
priority.127 He recommended “an audit to generate data on the use of antipsychotic medication for 
people with dementia in each primary care trust in England.”128 The initial results of this audit were 
published in July 2012,129 and will provide baseline data against which to measure the recommended 
reduction in the prescription of antipsychotic medication. His reasons against introducing a 
wholesale ban on these prescriptions included: the need to allow treatment for those people with 
BPSD for whom antipsychotic medication is the appropriate response (estimated at 36,000 of the 
180,000 people prescribed these medications annually);130 the possible negative effects of abrupt 
withdrawal from this treatment of those people currently prescribed antipsychotics;131 the effects of 
primary care services changing their referral behaviour, thus unsustainably increasing the burden on 
community mental health teams for older people;132 and the possibility of a “jump to different 
classes of ineffective medication being used.”133 In addition, Banerjee noted that increasing the 
complexity of prescription of antipsychotics “by making it bureaucratically complicated to initiate or 
maintain them” might be detrimental to “those who need to have these medications prescribed for 
other illnesses such as schizophrenia and bipolar disorder”, 134 demonising the medication and 
increasing the stigma of mental health problems. All of these are, of course, important 
considerations, but they could be addressed if these medications were controlled through increased 
regulation of off-label prescriptions. 
If controls on the prescription of antipsychotic medication were only introduced in respect of the 
off-label use of these drugs, then there would be no effect on their prescription for licensed 
indications, such as schizophrenia and bipolar disorder, nor on the use of Risperidone, the one 
antipsychotic that does have an MHRA marketing authorisation that covers BPSD. There would 
similarly be no need for the immediate withdrawal of drugs for those already prescribed them ‘off-
label’, though there would be an argument for introducing a requirement for prescribers to initiate a 
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review of all those who are currently prescribed medication off-label. Controls on off-label 
prescriptions would also prevent prescribers from simply switching from using antipsychotics to 
using off-label prescriptions of other neuroleptic drugs that are of similarly unproven effectiveness, 
or have different adverse side effect profiles. Introducing controls on off-label prescription would 
also have the benefit of ensuring that healthcare professionals engage in evidence-based practice 
wherever possible. It would provide a framework for gathering evidence of adverse effects, and for 
patient benefit. It would also ensure that medical professionals fulfil their responsibilities under the 
Mental Capacity Act 2005 when treating people who lack capacity in their best interests. Such a 
regulatory process would also protect other vulnerable patient groups from potential harms 
associated with off-label prescription, whilst concurrently continuing to allow medical professionals 
the flexibility to prescribe off-label where they think this is the best treatment for their patients. 
Finally, introducing tighter legal controls on off-label prescribing practices would have the secondary 
benefit of encouraging pharmaceutical companies to carry out the clinical tests necessary to 
determine the safety of alternate uses of their medications and thus increase the licensed 
treatments available. If existing medications were found not to have the safety profile necessary to 
be licensed for treating those conditions that they have been routinely prescribed off-label for, this 
would encourage the development of more effective medications, and save the costs of ineffective 
and unnecessary off-label prescription. 
 
